Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

NEXT STORY
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
PREV STORY
Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

author_avatar
NASDAQ Market News

Tissue Engineered Skin Substitutes Market to Cross $845 Million by 2025 – Global Industry Insights and Opportunities

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

Newark, NJ, June 28, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in ...

author_avatar
NASDAQ Market News